Creo Medical has published FY25 results to December 2025, updating on a period of significant change for the business. Revenue for the 12 months was £6.0m, up 50% YoY and in-line with guidance. Cost-control initiatives executed in FY25 saw the group deliver a significant improvement in the underlying EBITDA loss. Closing cash was £12.4m, and post-period the company has initiated steps to further strengthen and simplify the business by outsourcing manufacturing, disposing of its remaining stake i ....
